studies

mML - L1 - BRAF wild, immune chekpoint inhibitors vs. ipilimumab based treatment, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsCheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69] 0.40[0.23; 0.69]CheckMate 069 (BRAF wild type), 201510%109NAnot evaluable objective responses (ORR)detailed resultsCheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38] 12.96[3.47; 48.38]CheckMate 069 (BRAF wild type), 201510%109NAnot evaluable objective responses (ORR) (extension)detailed resultsCheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60] 13.00[3.48; 48.60]CheckMate 069 (BRAF wild type), 201510%109NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19] 3.39[1.40; 8.19]CheckMate 069 (BRAF wild type), 201510%108NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-07-01 16:13 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 128 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743